

**AMENDED CLAIMS**

[received by the International Bureau on 29 September 2003 (29.09.03);  
original claim 11 cancelled; all other claims unchanged]

1. A salt of 2S,3S enantiomer of 2-[ $\alpha$ -(2-ethoxy-phenoxy)-benzyl]-morpholine, which is the fumarate salt or the succinate salt thereof.
- 5 2. A salt, as claimed in claim 1, which is the fumarate salt.
3. A salt, as claimed in claim 1, which is the succinate salt.
- 10 4. A pharmaceutical composition comprising a salt, as claimed in claim 1, as active ingredient and a pharmaceutically acceptable excipient and /or carrier.
5. A salt, as claimed in claim 1, for the use as a medicament.
- 15 6. A salt, as claimed in claim 1, for use as selective norepinephrine reuptake inhibitor.
7. Use of a salt, as claimed in claim 1, in the manufacture of a pharmaceutical composition for use in treating a mammal, including humans, suffering from a disease state treatable by selective norepinephrine reuptake inhibition.
- 20 8. Method for treating a mammal in need of selective norepinephrine reuptake inhibition comprising administering to said mammal a therapeutically effective amount of a salt of SS-reboxetine, which is the fumarate salt or the succinate salt thereof.
- 25 9. A method, as claimed in claim 8, wherein the mammal is a human being.
10. A process for the preparation of a salt of 2S,3S enantiomer of 2-[ $\alpha$ -(2-ethoxy-phenoxy)-benzyl]-morpholine, which is the fumarate salt or the succinate salt thereof, which comprises: reacting 2-[ $\alpha$ -(2-ethoxy-phenoxy)-benzyl]-morpholine with (S) (+)  
30 mandelic acid so obtaining 2S,3S 2-[ $\alpha$ -(2-ethoxy-phenoxy)-benzyl]-morpholine mandelate; reacting 2S,3S 2-[ $\alpha$ -(2-ethoxy-phenoxy)-benzyl]-morpholine mandelate with a suitable basic agent so obtaining the corresponding free base; and reacting 2S,3S 2-[ $\alpha$ -(2-ethoxy-phenoxy)-benzyl]-morpholine with fumaric acid or succinic acid, respectively, followed by a controlled crystallization process.